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Abstract: Interest and research into the mechanisms and treatment of neuropathic pain have 
increased during recent years, but current treatment is still far from satisfactory (Dworkin et al 
2003; Attal et al 2006). The European Federation of Neurological Societies (EFNS) Task Force 
recently published guidelines for the pharmacological treatment of neuropathic pain (Attal et al 
2006). However, no particular consideration is given as to how the recommendations are appli-
cable to the elderly population. This paper will review the guidelines in relation to this population 
and evaluate the existing evidence relating to the use of these drugs in older persons.
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Background
There is currently a major shift occurring in the age distribution of the world’s 
population. In developed countries, the proportion of the population aged over 65 
will rise from 17.5% to 36.3% by 2050 and the over-80 age segment will more than 
triple (US Bureau of the Consensus, International Data, 2002). There is no clear 
consensus as to the deﬁ  nition of an “older person”. However, it is suggested that fur-
ther categorization of those over 65 may be useful: the young old can be deﬁ  ned as 
65–74 years, the middle old as 75–84 years and the oldest old as 85 and older (Leppik 
2006). However, there can be vast differences in people of the same chronological age. 
Therefore, there are also suggestions that each age group should be further sub-divided 
into: healthy, multiple medical problems and frail (Leppik 2006).
Pain is known to be a common problem in the elderly population, but it frequently 
goes unrecognized and under-treated (Helme and Gibson 1999; IASP 2006). The 
situation is complicated further by the increased potential for cognitive impairment 
and communication problems in the elderly (IASP 2006). Such is the concern about 
this issue that the International Association for the Study of Pain (IASP) made 
2006/07 the IASP “Global Year Against Pain in Older Persons” in an attempt to raise 
awareness and improve treatment. This subject is also part of their Core Curriculum 
for pain education. It has been identiﬁ  ed that there is an age-related increase in 
the prevalence of chronic pain at least until the seventh decade of life (Helme and 
Gibson 2001). Studies suggest that chronic pain affects over 50% of older persons 
living in the community setting and over 80% of nursing home residents (Ferrell 
1995; Helme and Gibson 2001).
Neuropathic pain results from disease or injury affecting the peripheral nerve, 
nerve root, spinal cord or brain. A large number of pathophysiological mechanisms 
have been delineated, and there is general agreement that in many persistent cases 
several of them are operant in maintaining the pain. Pain is commonly described as 
burning, shooting, smarting or aching, and local tenderness to mechanical and cool 
stimuli is common. The hallmark signs of neuropathic pain are reduced sensibility Clinical Interventions in Aging 2008:3(1) 112
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and increased sensitivity corresponding to the site of pain 
(Treede et al 2007). The newly formulated deﬁ  nition of 
neuropathic pain, “pain arising as a direct consequence of 
a lesion or disease affecting the somatosensory system” 
encompasses the important pathophysiological aspect 
that because of impairment of sensory pathways at some 
level the clinical examination is likely to show sensory 
abnormalities (Treede et al 2007). The diagnosis of 
neuropathic pain is based on evidence of a lesion present 
corresponding to the site of pain, and irrespective of 
commencement of treatment, etiological investigations 
are sometimes required.
Speciﬁ  c epidemiological data on neuropathic pain is 
limited. However, there is an estimated prevalence of 1.5% 
(Taylor 2006). In addition, there is a wide range of prevalence 
estimates reported in the literature for speciﬁ  c conditions. 
Between 8% and 50% of diabetics are estimated to have 
symptoms of diabetic neuropathy (Duck et al 1993; Partanen 
et al 1995). In a community survey of over 300 patients with 
diabetes the prevalence of painful neuropathy was 16% 
(Daousi et al 2004). Between 10% and 19% of back pain 
sufferers are estimated to have neuropathic pain (Carey et al 
1996; Loney and Stratford 1999). In a study of 916 patients 
with shingles, 18% of patients in their 50s experienced 
symptoms of post-herpetic neuralgia for 1 year or longer. 
However, in patients aged 70 or above this increased to 48% 
(Oaklander and Rissmiller 2002).
Treatment of neuropathic pain 
in the elderly
The treatment of neuropathic pain in the older person can 
be challenging and complex. The old are more vulnerable 
than younger persons since they often suffer from multiple 
medical and nutritional problems. This can limit treatment 
options with analgesic agents due to an increased risk of 
adverse effects and problems with complex drug interactions 
(Perucca et al 2006). In addition, older persons may have 
substantial differences in the absorption and clearance of 
drugs. Due to these factors there is an increased risk of 
excess sedation, confusion, constipation and urinary retention 
(Burris 2004).
A detailed literature review of pharmacokinetics in 
older persons found that changes occur due to age-related 
physiologic perturbations (Cusack 2004). However, 
the review suggests that age-related changes may be 
overshadowed by individual variation in disease, frailty 
and stress. It is also acknowledged that older persons take 
more medications and are more likely to have multiple 
medical problems, and this increases the risk of drug-drug 
and drug-disease interactions (Cusack 2004). It is suggested 
that the rate of drug metabolism, which occurs mainly in 
the liver, is often reduced with advancing age. In drugs that 
are mainly excreted by the kidney the rate of elimination is 
also generally reduced in the elderly. Therefore, the dose 
requirement for these types of drugs may be lower in many 
older patients (Cusack 2004).
Despite the fact the chronic pain is more common 
in older persons, the majority of pain treatment studies 
and trials have been conducted in young adult popula-
tions (IASP 2006). Until recently older subjects were 
routinely excluded from randomized controlled trials 
of pharmacotherapy. Even now, older people with 
co-morbid disease or those taking other medication are 
usually excluded (IASP 2006). Therefore, it is possible 
to suggest that there is signiﬁ  cant selection bias and that 
the “healthy” elderly subjects who are included in studies 
are not representative of the general elderly population. In 
particular it is acknowledged that most gerontologic studies 
of pharmacokinetics fail to include the very old (age 85 and 
over) and therefore the understanding of pharmacokinetics 
in this age group is very limited (Cusack 2004).
Several recent systematic reviews provide convergent 
guidance on pharmacological management of neuropathic 
pain (Dworkin, Backonja et al 2003; Finnerup et al 2005; 
Attal et al 2006; Moulin et al 2007). The recommendations 
based on these reviews come from randomized controlled 
trials from which it is usually difﬁ  cult to extract information 
speciﬁ  c to elderly patients. The general recommendation 
is to commence treatment with gabapentin/pregabalin or a 
tricyclic antidepressant (eg, amitriptyline or nortriptyline) 
and, in case of focal neuropathy, topical lidocaine. The 
choice between a gabapentinoid and a tricyclic is based on 
considerations on tolerability rather than quality or intensity 
of pain. Second line treatments include SNRIs (duloxetine 
and venlafaxine), some antiepileptic drugs (eg, lamotrigine), 
tramadol and topical capsaicin. Reservations are expressed 
in relation to strong opioids which feature as second or third 
line choices. Despite the general agreement between the three 
Task Force generated guidelines (Dworkin, Backonja et al 
2003; Attal et al 2006; Moulin et al 2007), there are some 
differences as shown in Table 1.
The EFNS Guidelines (Attal et al 2006) discuss treat-
ment options in speciﬁ  c neuropathic conditions, ie, painful 
polyneuropathies, post-herpetic neuralgia (PHN), trigeminal 
neuralgia (TN) and central pain (including spinal cord injury 
pain, post-stroke pain and multiple sclerosis). In addition, Clinical Interventions in Aging 2008:3(1) 113
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other less studied neuropathic conditions are included: 
post-traumatic/post-surgical nerve lesions, phantom limb 
pain and Guillain-Barré syndrome. In general, because of 
the few condition-speciﬁ  c controlled trials published, the 
authors suggest management along the same lines as those 
used in diabetic neuropathy and post-herpetic neuralgia 
for which ample data are available. Notable exceptions are 
lamotrigine in post-stroke pain, pregabalin in spinal cord 
injury pain, carbamazepine and oxcarbazepine in trigeminal 
neuralgia and cannabinoids in central pain related to multiple 
sclerosis (Attal et al 2006). In none of the comprehensive 
reviews are there age-speciﬁ  c recommendations, although 
reference to poorer tolerability in the elderly is occasionally 
made. The authors have generated their own approach to 
pharmacotherapy for the elderly with neuropathic pain 
(Table 2). It is a compilation of systematic reviews and guide-
lines with some modiﬁ  cations that reﬂ  ect safety concerns in 
this patient population.
Currently, the best evidence available suggests that 
the choice of medication in the elderly with neuropathic 
pain should be similar to that in the younger age group but 
commenced more cautiously and with particular attention to 
problems that may arise in the elderly. In this review we will 
discuss each drug in relation to the information and evidence 
available for its use in the elderly. We have drawn from two 
sources: from studies focusing on the elderly with other 
indications (eg, depression, epilepsy) or extrapolating from 
studies on postherpetic neuralgia in which the mean age of 
the participating patients has been >70 years.
Antidepressants
A recent review of the literature on the extent to which 
the elderly are represented in clinical trials of potential 
antidepressants found that elderly subjects aged 75 years and 
over were clearly under-represented (Giron et al 2005). The 
maximum age for inclusion for the majority of the clinical 
Table 1 Commonly used agents in neuropathic pain: choice of treatment as recommended by three task forces
Drug  Dworkin et al 2003  Attal et al 2006  Moulin et al 2007  Comment
TCA 1 1  1 
Gabapentin 1  1  1 
Pregabalin 1  1  1 
Tramadol 1  2  3 
Duloxetine NR  2  2 
Venlafaxine 2  2  2 
Lamotrigine 2  2  4 
Opioids 1  2 31  1Except methadone
Lidocaine 5%   1  22 2  2First-line in focal
plaster         neuropathy with 
       allodynia
Topical capsaicin  3  23 3  3PHN only
Valproate NR  2  4 
Topiramate NR  NE  4 
Bupropion 2  NR NR 
Paroxetine 2  NR4 NR  4+ve RCT 
       acknowledged
Citalopram 2  NE  4 
Mexiletine 3  NE 4 
Clonidine 3  NE 4 
NMDA   3  NE  NR 
antagonists      
Methadone  as other opioids  As other opioids  4 
Speciﬁ  c indications
Carbamazepine for TGN  1  1  1  No guideline 
       recommends  for 
       other  NPs
Oxcarbazepine for TGN  NR  1  NR 
Cannabinoids for central  NR  3  4 
pain in MS       
Note: 1ﬁ  rst-line treatment, 2second-line treatment, 3third-line treatment, 4fourth-line treatment. Note that only Moulin et al (2007) use the category of “fourth-line”.
NR, no recommendation or no discussion; NE, considered not effective.Clinical Interventions in Aging 2008:3(1) 114
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trials identiﬁ  ed was 65 years. There was no clear consensus 
on the deﬁ  nition of elderly; clinical trials that were reported 
to have been conducted in the elderly included subjects who 
were 50, 55, or 60 years and over. The highest age reported 
for a subject was 90 years. Pharmacological studies on 
healthy subjects were mainly done on young adults ranging 
from 18 to 65 years. Therefore, there is minimal evidence 
available in the literature about the safety and efﬁ  cacy of 
antidepressants in older persons, whether they are being used 
to treat depression and/or pain. The authors of the review 
(Giron et al 2005) recommend that regulatory bodies such 
as the Food and Drug Administration (FDA) and European 
Agency for the Evaluation of Medicinal Products (EMEA) 
should have special requirements relating to the elderly. For 
example, the inclusion of at least 25% of subjects aged 75 
years and over in studies of drugs that will be registered for 
use in the elderly.
Due to the fact that the majority of studies of antidepressants 
use a highly selective trial population, without signiﬁ  cant 
co-morbidity and with minimum numbers of elderly subjects, 
there are fundamental problems extrapolating the results to 
the elderly population as a whole (Parikh 2000). However, 
despite the lack of evidence, there are some recommendations 
in the literature relating to the use of antidepressants in the 
elderly. It is widely reported that older patients are more 
prone to side-effects and have greater difﬁ  culty tolerating 
doses of antidepressants that are likely to be of therapeutic 
value (Parikh 2000; ANZCA 2005). Older adults often 
require lower initial doses with slow titration and the initial 
dose should be one-half or lower than the normal starting 
dose (Antai-Otong 2006).
Tricyclic antidepressants (TCAs)
A recent study found a slight increase in sudden car-
diac death with TCA doses greater than 100 mg per day 
(Ray et al 2004). The study examined a retrospective cohort 
of 1487 patients with conﬁ  rmed sudden cardiac death in 
the community. Current users of TCAs had a dose-related 
increase in the risk of sudden cardiac death when compared 
with non-users of antidepressants. Rate ratios increased 
from 0.97 (95% conﬁ  dence interval (CI), 0.72–1.29) for 
doses lower than 100mg (amitriptyline or equivalent) to 
2.53 (95% CI, 1.04–6.12) for doses of 300 mg or more. The 
rate for SSRIs was 0.95 (95% CI, 0.42–2.15). There was 
no evidence that TCA doses lower than 100mg increased 
the risk of sudden cardiac death in subgroups deﬁ  ned by 
pre-existing cardiovascular disease, female sex, age 65 or 
older or use of amitriptyline. Although from this study the 
conclusion is that low doses of amitriptyline (or equivalent) 
may be used with a maximum dose of 100 mg, other well 
known anticholinergic, hypotensive and sedative side 
effects may pose a relative contraindication to tricyclic 
antidepressants, and a safer alternative in the very old may 
be gabapentin or pregabalin (Attal et al 2006) . Due to the 
risk of potential life-threatening side-effects some authors 
recommend baseline and follow-up electrocardiograms 
(ECGs) throughout treatment with tricyclic antidepressants 
(Dworkin, Backonja et al 2003). In Parikh’s (2000) advice 
on the posology of antidepressants in the elderly a lower 
starting and maintenance dose is advised for amitrip-
tyline, but no speciﬁ  c recommendations are made for 
nortriptyline.
In a head-to-head cross-over comparison study of 
tricyclic antidepressants and strong opioids for the treatment 
of PHN, 71 evaluable patients (mean age (SD) 71 (12) y) 
were allowed to self-titrate to maximum tolerated dose of 
160mg nortriptyline per day. A mean (SD) dose 89 (27) 
mg per day was better tolerated than morphine 91 (49) mg 
per day (Raja et al 2002). Two patients withdrew during 
nortriptyline treatment as opposed to seven during morphine 
treatment, and constipation, nausea and drowsiness were 
less common. However, 17% reported dizziness, signiﬁ  -
cantly more than when receiving morphine. Nortriptyline, 
however, showed a trend toward lesser efﬁ  cacy compared 
with morphine.
Due to the potential toxicity and adverse effects of TCAs, 
especially in the elderly population, consideration of dosing 
Table 2 Drug treatment of older persons with neuropathic pain
First line treatment
Tricyclic antidepressants (amitriptyline, nortriptyline)1
Gabapentinoids (gabapentin, pregabalin)
Lidocaine plaster 5% 
Carbamazepine and oxcarbazepine in TN2
Second line treatment
Tramadol
Lamotrigine
SNRIs (venlafaxine, duloxetine)
Third line treatment
Opioids (morphine, oxycodone, methadone)3
Cannabinoids in MS4
Citalopram and paroxetine5
Capsaicin
Note: 1In patients with no or stable cardiac conditions only
2Trigeminal neuralgia
3Despite efﬁ  cacy, concerns regarding tolerability make these drugs third line only
4Data on elderly patients extremely limited
5In peripheral neuropathies onlyClinical Interventions in Aging 2008:3(1) 115
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levels is important. Dose-effect and serum concentration-effect 
relationships have been reported in the literature. However, 
it is suggested that serum concentration-effect relationships 
may be more appropriate due to the large inter-individual 
variations in pharmacokinetics (Sindrup 2003). In a random-
ized, controlled trial of amitriptyline and carbamazepine in 
central post-stroke pain it was found that total plasma levels 
of amitriptyline varied greatly (56–925 nmol/l) despite the 
fact that all patients had tolerated the planned ﬁ  nal dose of 
75 mg/day (Leijon and Boivie 1989). The pain-relieving effect 
of amitriptyline appeared to correlate well with the total plasma 
concentration. Of patients with plasma concentration exceed-
ing 300 nmol/l, 70% were responders on the daily rating of 
the effect and 90% were responders on the global rating. This 
is compared to only 20% responders at plasma concentrations 
below 300 nmol/l. This would indicate that a total plasma 
concentration of 300 nmol/l should be used as a cut off point 
for the lowest effective drug level of amitriptyline when it is 
being used to treat neuropathic pain. This is lower than the 
reported corresponding level for the treatment of depression 
which is 500 nmol/l (Sindrup 2003).
Serotonin-noradrenaline reuptake 
inhibitors (SNRIs)
There is general agreement that SNRIs such as duloxetine 
and venlafaxine are safer to use than TCAs and are a better 
option in patients with cardiac disease. However, the risk of 
hyponatraemia due to the syndrome of inappropriate secretion 
of antidiuretic hormone (SIADH) is thought to be greater in 
elderly patients using selective serotonin re-uptake inhibitors 
(SSRIs)/SNRIs than those using TCAs (Antai-Otong 2006). 
Therefore, it is recommended that baseline electrolyte levels 
are checked and that sodium levels are closely monitored 
throughout treatment. The Committee on Safety of Medicines 
(CSM) has advised that hyponatremia should be considered in 
all patients who develop drowsiness, confusion or convulsions 
while taking an antidepressant (BNF 2007).
In a recent observational, naturalistic, multicenter, pro-
spective, open-label study of 97 patients older than 80 years 
with depressive syndrome, extended-release venlafaxine was 
found to be safe and effective (Baca et al 2006). At baseline, 
90.7% of the patients had additional medical conditions and 
83.5% were receiving concomitant medications. Adverse 
events were reported by 7 (7.2%) patients, but no serious 
adverse events were reported. The most frequent adverse 
events were dizziness, gastric pain and nausea. Treatment with 
venlafaxine over 24 weeks did not produce any clinically sig-
niﬁ  cant changes in blood pressure, heart rate or other variables 
such as weight. Baca et al (2006) suggest that venlafaxine is 
particularly useful in the treatment of the elderly due to a low 
potential for drug-drug interaction. This study provides valu-
able information because the study sample more accurately 
reﬂ  ects the typical elderly population.
Antiepileptic drugs
Antiepileptic drugs (AEDs) form an important part of the 
pharmacological management of neuropathic pain, but as 
is the case with TCAs they require a good deal of vigilance 
on the part of the prescribing clinician. Sodium channels 
blockers, especially carbamazepine and oxcarbazepine are 
effective in trigeminal neuralgia, but have well known major 
side effects. Their usefulness is limited in other neuropathic 
conditions (Attal et al 2006). A particular area of concern in 
the elderly is the risk of hyponatraemia with carbamazepine 
and oxcarbazepine. It is recommended that sodium levels 
should be monitored in the ﬁ  rst few months of treatment 
and that both drugs should be initiated with low dosages 
and slowly increased.
Further information on the use of AEDs in the elderly 
comes from studies on the treatment of epilepsy. AEDs are 
one of the main classes of drugs most commonly implicated 
as causing adverse drug reactions in the elderly (Perucca 
et al 2006). Available information on the pharmacokinetic 
properties of AEDs refers mainly to patients aged 70 or less, 
despite the fact that there is a high prevalence of AED use 
among elderly patients, for both the treatment of epilepsy 
and other indications such as neuropathic pain (Perucca 
et al 2006).
A recent paper reviewed two completed studies of AED 
use in the elderly and one still in progress (Leppik et al 
2006). The ﬁ  rst was a multicenter, randomized, double-
blind comparison between carbamazepine and lamotrigine 
in elderly patients with newly diagnosed epilepsy (Brodie 
at al 1999). No difference was noted between the drugs in 
time to ﬁ  rst seizure. However, in relation to the use of these 
drugs in neuropathic pain it is the additional data on adverse 
events that is of interest. Fewer patients taking lamotrigine 
(18%) dropped out of the study due to adverse events, 
compared to the patients taking carbamazepine (42%). 
Somnolence was reported signiﬁ  cantly more often in patients 
taking carbamazepine (29%) than those taking lamotrigine 
(12%, p < 0.01).
The other completed study was a three-arm, double-
blind, randomized clinical trial in patients aged 65 years or 
older with new-onset seizures, comparing the newer AEDs, 
gabapentin and lamotrigine, to old standard AED therapy Clinical Interventions in Aging 2008:3(1) 116
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with carbamazepine (Rowan et al 2005). 593 patients met 
the inclusion criteria, but 570 of those were male because the 
sample was taken from the United States Veterans Affairs 
(VA) system. This means that there is a signiﬁ  cant male 
gender bias in the study sample and therefore the results may 
not be generalizable to the elderly female population. Differ-
ences in early discontinuation among the drugs were apparent 
by 7 weeks. The most frequent discontinuations were with 
carbamazepine (27.3%), followed by gabapentin(17.4%, 
p < 0.01) and then by lamotrigine (10%, p < 0.00003). The 
primary outcome measure was retention in the study at 
52 weeks. Two hundred and seventy six patients (46.5%) 
completed the trial. Of those patients who withdrew from the 
study, 131 (41.3%) discontinued treatment due to adverse 
reactions to the study drug, and 33 (10%) due to uncontrolled 
seizures. These results concur with the ﬁ  ndings of a previous 
multi-centre double-blind trial in 150 elderly patients with 
newly diagnosed epilepsy, which found that lamotrigine 
was better tolerated than carbamazepine (Brodie et al 1999). 
These results provide some justiﬁ  cation for the choice of 
gabapentin and lamotrigine in elderly patients in certain 
neuropathic pain conditions in which efﬁ  cacy is shown. 
However, in case of trigeminal neuralgia, which commonly 
affects people over 65, the superior efﬁ  cacy of carbamaze-
pine over gabapentin and lamotrigine dictates its choice as 
ﬁ  rst line treatment.
Leppik (2005) suggests that for an AED to be ideal for 
the elderly it should have the following characteristics: no 
side effects or toxicity, complete oral absorption (related to 
water solubility), no drug-drug interactions, long half-life, no 
hepatic metabolism or enzyme induction/inhibition, no active 
metabolites, minimal protein binding, no effects on bone loss 
and a reasonable price. In general, the early AEDs available 
before 1980 have signiﬁ  cant potential for side-effects because 
they deviate from the ideal (Leppik 2005). Gastrointestinal 
drug absorption is altered with aging and AEDs that are 
highly insoluble (eg, phenytoin, carbamazepine) are gener-
ally poorly absorbed and complicate dosing regimes (Leppik 
2005). Lamotrigine is more soluble than the early AEDs and 
gabapentin is water soluble, but it relies on a rate-limiting 
transport system for absorption and has dose-dependent 
oral absorption (Leppik 2005). However, it is possible to 
suggest that both these drugs are closer to the ideal than the 
early AEDs.
Recommendations have been made in relation to the 
selection of AEDs for older patients with epilepsy and 
these can be applied to the treatment of older patients with 
neuropathic pain. Gabapentin and pregabalin are identiﬁ  ed as 
two of the newer AEDs that have the fewest drug interactions. 
These drugs exert no signiﬁ  cant effects on other medica-
tions likely to be used by the elderly and are not affected by 
other medications in terms of their serum levels or rate of 
metabolism (Leppik 2005). This is important because many 
elderly patients are on multiple medications and this increases 
the risk of drug-drug interactions. However, lamotrigine is 
metabolized by the liver and may have reduced levels when 
given with enzyme inducers (Leppik 2005).
Many newer AEDs also have better safety proﬁ  les than 
the older agents and gabapentin, pregabalin and lamotrigine 
have not had associated liver or bone marrow toxicity 
(Leppik 2005). Oxcarbazepine is considered to be safer 
than carbamazepine in relation to the fact it has no epoxide 
metabolite, has less hepatic induction and it does not depress 
white cell counts. The aplastic anemia and agranulocytosis 
that can be seen with carbamazepine may also not occur 
(Leppik 2005). However, the incidence of hyponatremia 
is higher with oxcarbazepine than carbamazepine (Bergey 
2004; Leppik 2005). It is suggested that oxcarbazepine 
should be avoided in elderly patients taking sodium-
depleting agents (eg, diuretics) (Bergey 2004). Gabapentin 
and pregabalin are both renally excreted and dose reductions 
should be made if there is signiﬁ  cant renal insufﬁ  ciency 
(Bergey 2004).
Cognitive side-effects are also of particular concern in 
the elderly because they may be more sensitive to small 
changes due to pre-existing cognitive dysfunction, multiple 
medications and concomitant medical problems (Leppik 
2005). Gabapentin, pregabalin and lamotrigine are classed 
as some of the newer AEDs that appear to have particularly 
favorable cognitive profiles compared with the older 
drugs (Leppik 2005). However, even these drugs do cause 
signiﬁ  cant central nervous system side effects, especially 
dizziness and drowsiness, which not infrequently lead to 
discontinuation of treatment. In older individuals the ﬁ  rst-
line AED should be one that causes less cognitive side-
effects, because these effects may often go unrecognized, 
particularly in patients with communication problems, or they 
may be attributed to other problems such as Alzheimer’s or 
cerebrovascular disease (Bergey 2004). Both gabapentin and 
pregabalin have been studied in PHN (Rowbotham et al 1998; 
Rice et al 2001; Dworkin, Corbin et al 2003; Sabatowski 
et al 2004). The mean age in these studies varied between 
71 and 76 years, with the oldest participants in their 90s. 
In one study 81% of the patients were over 65. The highest 
doses for gabapentin were 3600mg/day and for pregabalin 
600 mg/day. In the study by Rowbotham et al (1998), 83% Clinical Interventions in Aging 2008:3(1) 117
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tolerated a dose of at least 2400mg/day, and 13.3% in the 
gabapentin group withdrew from the study versus 9.5% in 
the placebo group. Pregabalin at doses of 300mg/day and 
higher led to withdrawal of 32% due to adverse effects (as 
opposed to 5% in the placebo group) but no drug-related 
serious adverse effects were reported (Dworkin, Corbin, 
et al 2003). It is unclear from these reports if the frequency 
and intensity of side effects correlated with age. Both gaba-
pentin and pregabalin are effective in reducing pain in PHN 
with numbers-needed-to-treat (50%) estimated at 4.6 (95% 
CI 3.7–6.0) (Finnerup et al 2005).
Tramadol
Tramadol hydrochloride is a synthetic analgesic that has a 
dual mechanism of action. It has a central analgesic effect 
with a weak afﬁ  nity for the µ-opioid receptor and also 
causes spinal inhibition of the reuptake of noradrenaline 
and serotonin (Budd 1999; Schnitzer 1999). The EFNS 
Guidelines (Attal et al 2006) recommend that tramadol 
should be initiated at low dosages of 50 mg once daily 
in elderly patients and then titrated as tolerated. A dose 
adjustment is not usually necessary in elderly patients (up 
to 75 years) without clinically manifest hepatic or renal 
insufﬁ  ciency (Schnitzer 1999). In elderly patients (over 
75 years) elimination may be prolonged. Therefore, if 
necessary, the dosage interval is to be extended according to 
the patients requirements. Tramadol can induce convulsions 
and increase the potential for SSRIs, TCAs, anti-psychotics 
and other seizure threshold-lowering medicinal products to 
cause convulsions. In isolated cases there have been reports 
of serotonin syndrome in a temporal connection with the 
therapeutic use of tramadol in combination with other 
serotonergic medicinal products such as selective serotonin 
SSRIs or with MAO inhibitors (Grunenthal 2006). It is 
essential that these precautions are taken into consideration 
when tramadol is being used in elderly patients because they 
are often taking multiple medications which increase the risk 
of drug-drug interactions and adverse effects.
A randomized, double-blind, placebo-controlled trial 
was recently carried out to evaluate the efﬁ  cacy and safety 
of a combined paracetamol 325 mg and tramadol 37.5 mg 
tablet for the treatment of ﬂ  are-ups of osteoarthritis pain in 
elderly patients (aged 65 and older) (Rosenthal et al 2004). 
The patients were permitted to take one to two tablets four 
times daily. The combination was found to be signiﬁ  cantly 
superior to placebo for average daily pain intensity and pain 
relief. The most common treatment related adverse events 
in the tramadol/paracetamol group were nausea (18.8%), 
vomiting (13%), dizziness (11.6%) and constipation (4.3%). 
The low incidence of constipation (4.3% vs 2.3% in placebo 
group) and somnolence (2.9% vs 2.3% in placebo group) 
were worthy of note. The study concludes that the tolerability 
proﬁ  le of this combination medication, especially the low 
rates of constipation and somnolence, make it an attrac-
tive alternative to traditional opioid analgesics for elderly 
patients. However, the duration of the study was only 10 days 
and therefore one must exercise caution in extrapolating these 
results to long-term use in chronic pain conditions.
Strong opioids
Strong opioids are increasingly being used for patients with 
chronic benign pain. In 2005 the British Pain Society pub-
lished recommendations for the appropriate use of opioids 
for persistent non-cancer pain, but no speciﬁ  c guidance is 
offered in relation to elderly patients. Strong opioids have 
also been shown to be effective in the treatment of chronic 
neuropathic pain (Gimbel et al 2003; Watson et al 2003). 
The EFNS guidelines (Attal et al 2006) recommend their 
use as second-line treatment in a number of neuropathic 
pain conditions, but again no speciﬁ  c guidance is provided 
for their use in elderly patients. It is suggested that elderly 
patients may require less opioid than younger patients and in 
the post-operative setting there is evidence of an age-related 
2–4 fold decrease in morphine and fentanyl requirements 
(Macintyre and Jarvis 1996; Woodhouse and Mather 1997; 
Gagliese et al 2000).
Elderly patients who are commenced on strong opioids 
require regular monitoring because reduced renal function 
can lead to a more rapid accumulation of active opioid 
metabolites (ANZCA 2005). Both morphine and oxycodone 
produce active metabolites that can accumulate causing 
increased therapeutic and adverse effects (Johnson 2007). 
It is recommended that both drugs are used cautiously in 
patients with renal dysfunction, with careful monitoring 
and dose adjustment if necessary. Fentanyl has no active 
metabolites, but a dose reduction is still advised because 
clearance is reduced in patients with moderate to severe 
uremia (Johnson 2007).
There is a paucity of research in the literature on the 
use of strong opioids in elderly patients with chronic pain. 
However, one recent longitudinal study of 10,372 nurs-
ing home residents concluded that the use of long-acting 
opioids may be a relatively safe option in the management 
of persistent, non-malignant pain, yielding beneﬁ  ts in 
functional status and social engagement (Won et al 2006). 
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of daily living (ADL) status and social engagement was 
observed in patients taking long-acting opioids compared 
to those taking non-opioids. There were no signiﬁ  cant 
declines in cognitive function, ADL status, mood status 
or social engagement over 6 months with the use of any 
analgesics. Overall, a trend towards a decreased risk for 
falls over 6 months was seen with the use of any analgesics. 
Long-term use of opioids did not signiﬁ  cantly increase the 
risk of falls. The authors acknowledge that the study has 
limitations because it was necessary to restrict the sample 
to persons taking analgesics in only one class for 6 months; 
whereas in reality, many patients may take analgesics from 
a number of different classes. However, this is the only 
study identiﬁ  ed that examines quality of life outcomes of 
chronic analgesic use in frail elderly persons.
In the two studies published on the efﬁ  cacy of morphine 
and oxycodone, the beneﬁ  t from moderately high doses 
(mean dose 89 mg of morphine and 45mg of oxycodone) 
of both drugs was well documented with a joint NNT of 
2.6 (95% CI 2.0–3.8) (Finnerup et al 2005). Common side 
effects included constipation nausea, drowsiness, and loss 
of appetite but no cognitive impairment was reported (Wat-
son and Babul 1998; Raja et al 2002). Side effects led to 
withdrawal in over one-quarter of patients (mean age (SD) 
71 (12) years) on morphine despite its apparent superiority 
over placebo and nortriptyline. While tolerability in studies 
with long up-and-down titration protocols and a short (2-
week) maintenance period give some insight of the efﬁ  cacy 
(Raja et al 2002), it is not well known if effectiveness con-
tinues long-term in this condition and to what extent dose 
adjustment is needed.
Topical agents
Topical capsaicin is seen as a modestly effective treatment in 
PHN and diabetic neuropathy (Bernstein et al 1989; Watson 
et al 1993). To maintain the effect, the cream must be applied 
over the painful area several times a day and initially causes 
severe burning, leading to at least 30% of patients stopping 
treatment prematurely. It is possible to suggest that the use of 
capsaicin in elderly frail patients with cognitive impairments 
may not be advisable due to the potential for inadvertent expo-
sure of other areas of the body. If capsaicin was accidentally 
rubbed into the eyes or onto other mucous membranes signiﬁ  -
cant irritation and discomfort/distress would be caused.
A topical agent recently licensed in the United Kingdom 
(UK) for the treatment of PHN is the 5% lidocaine plaster. 
Due to its low systemic absorption this treatment is considered 
safe and only local adverse effects (mild skin reactions) 
have been reported. Several authors recommend it is used as 
ﬁ  rst-line treatment in patients with PHN with a small area of 
pain / allodynia and state that it may be preferred as a treatment 
for elderly patients due to excellent tolerability (Finnerup 
et al 2005; Attal et al 2006; Moulin et al 2007). A recent 
review of the literature concludes that the safety, tolerability, 
and efﬁ  cacy of the lidocaine patch 5%, a targeted peripheral 
analgesic, has been well established in PHN (Gammaitoni et al 
2003). The review reports that potential efﬁ  cacy in other 
neuropathic and non-neuropathic pain conditions has also 
been suggested in recent case reports and studies. Several 
pharmacokinetic studies have demonstrated minimal systemic 
absorption with 12-, 18-, and 24-hour/day dosing. Due to the 
low mean maximum plasma concentrations there is minimal 
risk for systemic toxicity or drug-drug interactions. The most 
common adverse events generally involve mild skin reac-
tions and there have been no drug-drug interactions noted 
in clinical trials (Gammaitoni et al 2003). All these factors 
make this an ideal drug for use in the elderly and it appears 
that the risk of adverse events is minimal even in those with 
multiple medical problems and concomitant medication use. 
However, there is only sufﬁ  cient evidence in the literature at 
the current time for the use of the 5% lidocaine plaster in the 
treatment of PHN and it is only licensed in the UK for this 
indication. It is currently recommended for use in PHN and 
focal neuropathy (Finnerup et al 2005; Attal et al 2006), but 
not for all neuropathic pain conditions.
Conclusion
Pharmacotherapy remains the mainstay of management of 
neuropathic pain in the elderly. There is a relative paucity 
of studies available from which speciﬁ  c guidelines can be 
produced. However, indirect evidence suggests that current 
guidelines aimed at the neuropathic pain population in general 
can also be adopted for the older person’s treatment, given that 
potential alterations in pharmacokinetics and pharmacodynam-
ics of various drugs are taken into account and contraindica-
tions and tolerability issues are strictly observed. In general, 
drugs should be commenced at a lower dose and be upwardly 
titrated more slowly than in middle-aged and young people. 
Studies in PHN, which include a majority of patients who are 
elderly, show clinically signiﬁ  cant efﬁ  cacy from tricyclic anti-
depressants, opioids and gabapentinoids and moderate-to-good 
tolerability in most cases. Reports of serious side effects typical 
for the elderly are very few. Tricyclic antidepressants warrant 
a word of caution because of their cardiotoxicity and other 
problems. In general, studies in the treatment of neuropathic 
pain in the elderly, other than PHN, and especially studies in Clinical Interventions in Aging 2008:3(1) 119
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the oldest-old that evaluate the effectiveness and tolerability 
of current and new drugs are desperately needed.
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